P roinflammatory cytokines (PICs) are increased in cardiovascular disease states, [1][2][3] and studies over the past decade have suggested that blood-borne and brain PICs contribute to the neurohumoral activation in heart failure (HF) 4 and in some forms of hypertension. 5 We recently demonstrated that the subfornical organ (SFO), a circumventricular organ that lacks a blood-brain barrier, is an important central nervous system sensor of peripheral inflammation, mediating the effects of circulating PICs on autonomic and cardiovascular function. 6 However, the mechanisms by which PICs act within the SFO to influence neurohumoral excitation have not been examined.
whether PIC activation of the SFO affects the neurochemical milieu downstream in the PVN.
Methods

Animals
Adult male Sprague-Dawley rats (300-350 g) were purchased from Harlan (Indianapolis, IN). Animals were housed in Animal Care Facility at the University of Iowa and fed rat chow ad libitum. All experimental procedures were approved by the University of Iowa Institutional Animal Care and Use Committee. The experimental protocols were conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
Experimental Protocols
1. Urethane-anesthetized rats underwent electrophysiological and hemodynamic recording studies to determine the sympathetic responses to SFO microinjections of tumor necrosis factor (TNF)-α (25 ng) or interleukin (IL)-1β (25 ng), preceded 10 minutes by SFO microinjection of vehicle (VEH), the AT 1 R blocker losartan (1 μg), the ACE inhibitor captopril (1 μg), or the COX-2 activity inhibitor NS-398 (2 μg). 2. Urethane-anesthetized rats received an SFO microinjection of TNF-α (25 ng), IL-1β (25 ng) or VEH and were euthanized 4 hours later to collect SFO and PVN tissue to determine the mRNA expression of AT 1 R, ACE, COX-2 and COX-1, TNF-α, IL-1β, the p55 TNF-α receptor (TNFR1), and the IL-1β receptor (IL-1R). 3. Urethane-anesthetized rats were transcardially perfused with heparinized saline followed by 4% paraformaldehyde in 0.01 mol/L PBS to collect brain tissue for immunofluorescent staining to determine whether TNFR1 and IL-1 receptor accessory protein (IL-1RAcP) immunoreactivity colocalized with AT 1 R-like, ACE, COX-2, and PGE 2 receptor EP 3 immunoreactivity in the SFO.
Drug Administration
SFO microinjection of TNF-α, IL-1β, losartan, captopril, and NS-398 was performed via a 35-gauge cannula inserted in a 30-gauge guide cannula that was placed 0.9 mm posterior to bregma, along the midline of the skull (see online-only Data Supplement for details). TNF-α and IL-1β were purchased from Fitzgerald (Acton, MA) and Millipore (Billerica, MA), respectively. Losartan and captopril were purchased from Sigma (St. Louis, MO). All these drugs were dissolved in artificial cerebrospinal fluid for SFO microinjection. NS-398 was purchased from Tocris (Ellisville, MO), and was first dissolved in dimethyl sulfoxide and then diluted in artificial cerebrospinal fluid to make a 5% final dimethyl sulfoxide concentration.
Statistical Analysis
All values are expressed as the means±SEM. The significance of differences among groups was analyzed by 2-way repeated-measure ANOVA followed by post hoc Fisher's test. Student's t test was used to determine statistical significance between paired data for a single comparison. P<0.05 was considered to indicate statistical significance.
Specific Materials and Methods
Please see the online-only Data Supplement.
Results
Hemodynamic and Sympathetic Effects of SFO Microinjections
TNF-α SFO microinjection of TNF-α (n=6; Figure 1A , 1E, 1F, and 1G) elicited significant increases in mean blood pressure (MBP), heart rate (HR), and renal sympathetic nerve activity (RSNA) in the rats pretreated with SFO microinjections of VEH. These excitatory responses began within 15 to 20 minutes after the TNF-α microinjection. The maximum responses of MBP (19.8±2.7 mm Hg), HR (75.2±8.5 bpm), and RSNA (81.9±9.2% change) occurred 2 to 3 hours after the TNF-α microinjection and remained at higher than baseline level for at least 5 hours. Pretreatment with SFO microinjection of losartan ( Figure 1B , 1E, 1F, and 1G), captopril ( Figure 1C , 1E, 1F, and 1G), or NS-398 ( Figure 1D, 1E 
IL-1β
Microinjection of IL-1β into the SFO (n=6; Figure 2A , 2E, 2F, and 2G) also induced substantial and long-lasting increases in MBP, HR, and RSNA in the rats pretreated with SFO microinjections of VEH. The excitatory responses to IL-1β began within 15 to 20 minutes of the IL-1β microinjection. The peak increase in MBP (20.0±2.5 mm Hg) occurred at 1 to 2 hour and was sustained at a higher than baseline level for the remainder of the 3 to 5 hour recording period. The peak increase in HR (81.2±10.5 bpm) and RSNA (83.5±10.6% change) occurred 2 to 3 hours after the IL-1β microinjection and lasted for at least 5 hours. Pretreatment with SFO microinjection of losartan ( Figure 2B , 2E, 2F, and 2G), captopril ( Figure 2C , 2E, 2F, and 2G), or NS-398 ( Figure 2D , 2E, 2F, and 2G) significantly attenuated the MBP (11.2±2. 
Histological Confirmation of SFO Microinjection
At the conclusion of each experiment, SFO microinjection sites were examined by light microscopy. Microinjection sites were confirmed by the presence of Pontamine sky blue throughout the SFO, with no dye present in the 3rd ventricle ( Figure S1 ). Figure 3C and 3D). Similarly, 4 hours after SFO microinjection of TNF-α, TNF-α and IL-1β mRNA were significantly increased in the SFO (2.58±0.22 versus 1.00±0.09 and 2.30±0.38 versus 1.03±0.09 fold, respectively) and the PVN (2.34±0.16 versus 1.03±0.12 and 2.00±0.13 versus 1.01±0.07 fold, respectively), compared with microinjection of VEH ( Figure 3E and 3F). TNFR1 and IL-1R mRNA levels were also increased in both SFO (2.81±0.25 versus 1.01±0.11 and 2.11±0.34 versus 1.00±0.09 fold, respectively) and PVN (2.55±0.18 versus 1.03±0.12 and 1.83±0.12 versus 1.09±0.11 fold, respectively), compared with SFO microinjection of VEH ( Figure 3G and 3H).
IL-1β
The IL-1β microinjection, like the TNF-α microinjection, significantly increased AT 1 R and ACE mRNA in the SFO (AT 1 R, 3.06±0.32 versus 1.00±0.10; ACE, 2.65±0.27 versus 1.01±0.12 fold) and PVN (AT 1 R, 2.01±0.23 versus 1.08±0.09; ACE, TNF-α and IL-1β mRNA levels were significantly elevated in the SFO (2.39±0.27 versus 1.00±0.10 and 3.02±0.43 versus 1.10±0.15 fold, respectively) and the PVN (2.17±0.25 versus 1.03±0.11 and 2.33±0.16 versus 1.04±0.16 fold, respectively) compared with VEH ( Figure 4E and 4F ). TNFR1 and IL-1R mRNA levels were also augmented in SFO (2.60±0.23 versus 1.06±0.09 and 2.66±0.45 versus 1.10±0.12 fold, respectively) and PVN (2.37±0.17 versus 1.09±0.12 and 2.30±0.16 versus 1.00±0.11 fold, respectively), compared with VEH ( Figure 4G and 4H).
SFO microinjection of TNF-α and IL-1β had no significant effects on the mRNA levels of any of these RAS and inflammatory elements in the cortex (Figures 3 and 4) . 
Discussion
Our previous work has demonstrated that blood-borne PICs induce sympathetic activation and a pressor response 6, 23 and that the SFO plays an important role in mediating those effects. 6 The present study examined potential mechanisms in the SFO, and downstream in the PVN, that might mediate cardiovascular and autonomic responses to circulating PICs. Novel findings of this study are (1) localized microinjections of TNF-α and IL-1β into the SFO increase BP, HR, and RSNA, closely mimicking the effects of systemically administered TNF-α and IL-1β; (2) pretreating the SFO with microinjections of agents that counter RAS and COX-2 activity attenuates the cardiovascular and sympathetic responses to SFO microinjections of PICs; (3) TNF-α and IL-1β receptor immunoreactivity is colocalized with AT 1 R-like, ACE, COX-2, and EP 3 receptor immunoreactivity on SFO neurons; and (4) SFO microinjections of TNF-α and IL-1β upregulate mRNA for key components of the RAS (ACE and AT 1 R) and mediators of central inflammation (TNF-α and IL-1β, their receptors and COX-2) in both SFO and PVN. These findings suggest that the SFO-mediated acute sympathoexcitatory response to PICs depends on the ambient level of RAS and COX-2 activity and that PICs act within the SFO to increase RAS and COX-2 activity. This study provides new insights into the central mechanisms driving neurohumoral excitation in cardiovascular disorders like HF and hypertension.
Central nervous system markers of inflammation and RAS activity are dramatically upregulated in cardiovascular autonomic regions of the brain in experimental models of HF 24, 25 and hypertension 5, 26, 27 and contribute to the increased sympathetic activity characteristic of those conditions. However, the signals that direct the brain to upregulate these excitatory systems are still poorly understood. Afferent neural and humoral signals relaying compromised cardiac, vascular, and renal status likely both contribute. As a forebrain circumventricular organ that is exposed to blood-borne humors and projects directly to cardiovascular autonomic nuclei, the SFO is uniquely positioned to regulate central neural responses to peripheral stresses. Previous work from our laboratory has demonstrated that blood-borne ANG II upregulates AT 1 R mRNA and protein in the SFO. 28 The present study demonstrates that TNF-α and IL-1β can also upregulate AT 1 R mRNA in the SFO, as well as the mRNA for ACE, TNF-α, and IL-1β and their receptors and COX-2, the rate limiting enzyme in the production of PGE 2 . Thus, in conditions like hypertension and HF in which circulating ANG II and PICs are both increased, both may contribute to neuro-excitation in the SFO.
In addition, the present study demonstrates that PICs, acting on their receptors in the SFO, also increase RAS and COX-2 activity downstream in the PVN, a source of presympathetic neurons innervating preganglionic sympathetic neurons in the intermediolateral column of the spinal cord both directly and indirectly via presympathetic neurons in the rostral ventrolateral medulla. Thus, the effects of PICs in the SFO may increase the excitability of PVN neurons to a variety of ascending and descending neural inputs that ultimately determine the level of sympathetic nerve activity.
The present study demonstrates that PIC receptors are present on SFO neurons expressing RAS components and inflammatory mediators and that mRNA expression of these elements in the SFO and in the PVN is increased when measured 4 hours after local microinjection of PICs. Although these changes may well contribute to the increases in sympathetic drive observed in HF and hypertension, in which circulating levels of PICs are chronically elevated, they cannot account for the SFO-mediated acute (within 10-20 minutes) increases in sympathetic drive and arterial pressure induced by intravenous, 6 intracarotid, 6 and direct SFO microinjection of PICs in normal rats. There are several potential explanations for these early excitatory responses. PIC binding to G-protein coupled receptors in the SFO may activate G-protein-dependent signaling cascades, such as protein kinase A and protein kinase C, to modulate both ionotropic and metabotropic receptors. [29] [30] [31] PICs can activate mitogen-activated protein kinase signaling, which has been reported to have acute and chronic influences on sympathetic nerve activity in normal and pathophysiological conditions. 32 For example, extracellular signal-regulated protein kinases 1 and 2 can acutely phosphorylate the voltagegated potassium channel (Kv) subunit Kv4.2 in neurons, 33 reducing the transient outward potassium current that modulates neuronal excitability. 34 PICs may also interact with fast neurotransmitter systems to modulate neuronal excitability and synaptic transmission. TNF-α can increase local glutamate concentration in the synaptic cleft by stimulating glutamate release from microglia or inhibiting the glutamate retake by astrocytes 35 and can potentiate glutamate-mediated neuronal excitation by modulating NMDA and GABA receptor function. 36 Finally, like ANG II, PICs may induce ER stress, 37 which has been associated with ANG II-induced hypertension. 38 One or more of these mechanisms may account for acute sympathetic and cardiovascular responses to PICs, and all may contribute to chronic sympatho-excitation in pathophysiological states.
A novel finding of this study is the ability of pretreatment with agents that block RAS and COX-2 activity to substantially reduce the acute sympathetic and cardiovascular responses to the SFO PIC microinjections. This effect occurs far too early to be explained by a reduction in the activity of PIC-stimulated production of ACE, AT 1 R, and COX-2. A more likely explanation might be that ambient levels of ANG II and PGE 2 sustain a basal level of neuronal excitability that is reduced by pretreatment with the inhibitors of RAS and COX-2 activity, rendering presympathetic neurons less responsive to acutely administered PICs.
Perspectives
The SFO is an active interface between peripheral and central inflammation. We previously demonstrated a critical role for the SFO in the cardiovascular and sympathetic response to blood-borne PICs. 6 The present study offers some initial insights into the mechanisms by which PICs, which do not directly activate ion channels to excite neurons, might act within the SFO to induce sympathetic excitation. We found that the acute excitatory response to PICs is substantially reduced by agents that inhibit RAS and COX-2 activity, suggesting that the PIC response is dependent on a basal state of neuronal excitability sustained by these 2 mechanisms. We also observed colocalization of AT 1 R-like, ACE, COX-2 and EP 3 receptor immunoreactivity with PIC receptor immunoreactivity on SFO neurons, and a PIC-induced upregulation of mRNA for ACE, AT 1 R, TNF-α, TNFR1, IL-1β, IL-1R, and COX-2 not only in the SFO but also downstream in the PVN, suggesting that PICs may act within the SFO to induce a chronic, sustained increase in the production of RAS and inflammatory mediators in these 2 critical cardiovascular regulatory regions of the brain. By doing so, PICs may facilitate the central nervous system actions of other excitatory mediators, like ANG II and aldosterone, that circulate in chronic cardiovascular disease states like hypertension and HF. Because it lacks a blood-brain barrier, the SFO is potentially an ideal target for systemically administered drugs that can modulate central nervous system mechanisms. Further delineation of the molecular mechanisms by which PICs induce changes in the neurochemical milieu of the SFO may lead to the discovery of new therapeutic agents for hypertension, HF, and other cardiovascular-related diseases with an inflammatory component. 
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What Is New?
• Subfornical organ (SFO) microinjection of tumor necrosis factor (TNF)-α or interleukin-1β induces pronounced increases in blood pressure, heart rate, and renal sympathetic nerve activity that are largely reduced by pretreatment with the angiotensin II type-1 receptor blocker losartan, the angiotensin-converting enzyme inhibitor captopril, or the cyclooxygenase-2 activity inhibitor NS-398.
• SFO microinjection of TNF-α or interleukin-1β increases the mRNA expression of angiotensin-converting enzyme, angiotensin II type-1 receptor, cyclooxygenase-2, TNF-α, interleukin-1β, the p55 TNF-α receptor TNFR1, and the interleukin-1 receptor in the SFO and paraventricular nucleus.
What Is Relevant?
• Interaction of proinflammatory cytokines with renin-angiotensin system and cyclooxygenase-2/prostaglandin E2 in the SFO may be an important mechanism contributing to the neurohumoral activation in hypertension and heart failure.
• Proinflammatory cytokines, acting on SFO, upregulate excitatory and inflammatory mediators downstream in the paraventricular nucleus, a source of presympathetic neurons.
Summary
The data demonstrate that proinflammatory cytokines act within the SFO to elicit a sympathoexcitatory response mediated by the renin-angiotensin system and by cyclooxygenase-2/prostaglandin E2 and to upregulate the expression of components of the brain renin-angiotensin system and mediators of inflammation in the SFO and downstream in the paraventricular nucleus. These mechanisms may contribute to the sympathoexcitatory influence of circulating proinflammatory cytokines in cardiovascular disease states. 
